Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: Insights from the Dartmouth Dynamic Registry†
Jeremiah R. Brown PhD
The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH
Search for more papers by this authorDavid J. Malenka MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorJames T. DeVries MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorJohn F. Robb MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorJohn E. Jayne MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorBruce J. Friedman MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorBruce D. Hettleman MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorNathaniel W. Niles MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorAaron V. Kaplan MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorAnton C. Schoolwerth MD
Section of Nephrology and Hypertension, Department of Medicine, Dartmouth- Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorCorresponding Author
Craig A. Thompson MD, MMSc
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Section of Cardiology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756Search for more papers by this authorJeremiah R. Brown PhD
The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH
Search for more papers by this authorDavid J. Malenka MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorJames T. DeVries MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorJohn F. Robb MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorJohn E. Jayne MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorBruce J. Friedman MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorBruce D. Hettleman MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorNathaniel W. Niles MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorAaron V. Kaplan MD
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorAnton C. Schoolwerth MD
Section of Nephrology and Hypertension, Department of Medicine, Dartmouth- Hitchcock Medical Center, Lebanon, NH
Search for more papers by this authorCorresponding Author
Craig A. Thompson MD, MMSc
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Section of Cardiology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756Search for more papers by this authorConflict of interest: Nothing to report.
Abstract
Objectives: We sought to determine if transient and persistent elevations in creatinine following percutaneous coronary intervention (PCI) resulted in poor survival. Background: Limited survival data exist that defines the natural survival history of transient and persistent renal dysfunction following interventional PCI cases. Methods: Data were collected prospectively on 7,856 consecutive patients undergoing PCI from January 1, 2000 to July 31, 2006. Ninety-three patients were excluded due to pre-PCI dialysis. Patients were stratified into three categories of renal dysfunction: no renal dysfunction from baseline (<0.5 mg/dL increase in creatinine within 48 hr of the procedure), transient renal dysfunction (≥0.5 mg/dL increase in creatinine within 48 hr with return to normal within 2 weeks), and persistent renal dysfunction (≥0.5 mg/dL increase in creatinine without returning to normal within 2 weeks of the procedure). Mortality was determined by comparing with the Social Security Death Master File. Results: Median survival was 3.2 years (mean 3.4). Renal dysfunction occurred in 250 patients (0.5 mg/dL increase in creatinine). Survival was significantly different between patients at 1, 3.2, and 7.5 years (P-value < 0.001): no renal dysfunction (95%, 88%, 75%), with transient (61%, 42%, 0%), and with persistent (58%, 44%, 36%) renal dysfunction. Patients with transient or persistent renal dysfunction had a twofold–threefold increased risk of 7.5-year mortality compared with patients with no renal dysfunction. Conclusions: Both transient and persistent postprocedural renal dysfunction are prognostically significant for mortality during extended follow-up. Renal dysfunction should be closely monitored before and after PCI. © 2008 Wiley-Liss, Inc.
REFERENCES
- 1 McCullough PA,Adam A,Becker CR,Davidson C,Lameire N,Stacul F,Tumlin J. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006; 98: 5K–13K.
- 2 Mehran R,Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006 (100): S11–S15.
- 3 McCullough PA,Wolyn R,Rocher LL,Levin RN,O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368–375.
- 4 Rihal CS,Textor SC,Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259–2264.
- 5 Finn WF, The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant 2006; 21: i2–i10.
- 6 Mathew R,Haque K,Woothipoom W. Acute renal failure induced by contrast medium: steps towards prevention. BMJ 2006; 333: 539–540.
- 7
Anonymous.
Executive summary-K/DOQI clinical practice guidelines.
Am J Kidney Dis
2002;
39 (
Suppl 1):
S17–S31.
10.1053/ajkd.2002.30940 Google Scholar
- 8 Best PJ,Reddan DN,Berger PB,Szczech LA,McCullough PA,Califf RM. Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J 2004; 148: 230–242.
- 9 Levy EM,Viscoli CM,Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489–1494.
- 10 Cigarroa RG,Lange RA,Williams RH,Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86 (6 Part 1): 649–652.
- 11 Briguori C,Airoldi F,D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007; 115: 1211–1217.
- 12 Briguori C,Colombo A,Violante A, et al. Standard vs. double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004; 25: 206–211.
- 13 Schisterman EF,Whitcomb BW. Use of the Social Security Administration Death Master File for ascertainment of mortality status. Popul Health Metr 2004; 2: 2.
- 14 Mehran R,Aymong ED,Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393–1399.
- 15 Ghali WA,Quan H,Brant R,van Melle G,Norris CM,Faris PD,Galbraith PD,Knudtson ML. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001; 286: 1494–1497.
- 16 Gruberg L,Mintz GS,Mehran R,Gangas G,Lansky AJ,Kent KM,Pichard AD,Satler LF,Leon MB. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36: 1542–1548.
- 17 Rocha-Singh KJ,Ahuja RK,Sung CH,Rutherford J. Long-term renal function preservation after renal artery stenting in patients with progressive ischemic nephropathy. Catheter Cardiovasc Interv 2002; 57: 135–141.
- 18 Marenzi G,Assanelli E,Marana I, et al. N-acetylcysteine and contrast- induced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773–2782.
- 19 Rich MW,Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990; 150: 1237–1242.
- 20 Chertow GM,Burdick E,Honour M,Bonventre JV,Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365–3370.
- 21 Dangas G,Iakovou I,Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95: 13–19.
- 22 Nikolsky E,Mehran R,Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004; 94: 300–305.
- 23 Lindsay J,Canos DA,Apple S,Pinnow E,Aggrey GK,Pichard AD. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatine kinase-MB versus rise of serum creatinine. Am J Cardiol 2004; 94: 786–789.
- 24 Sadeghi HM,Stone GW,Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108: 2769–2775.
- 25 Gupta R,Gurm HS,Bhatt DL,Chew DP,Ellis SG. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv 2005; 64: 442–448.
- 26 Lindsay J,Apple S,Pinnow EE,Gevorkian N,Gruberg L,Satler LF,Pichard AD,Kent KM,Suddath W,Waksman R. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003; 59: 338–343.
- 27 Recio-Mayoral A,Chaparro M,Prado B,Cozar R,Mendez I,Banerjee D,Kaski JC,Cubero J,Cruz JM. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 2007; 49: 1283–1288.
- 28 Freeman RV,O'Donnell M,Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90: 1068–1073.
- 29 Brown JR,DeVries JT,Piper WD, et al. Serious Renal dysfunction after percutaneous coronary intervention can be predicted. Am Heart J 2008; 155: 260–266.
- 30 Barrett BJ,Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354: 379–386.
- 31 McCullough PA,Adam A,Becker CR,Davidson C,Lameire N,Stacul F,Tumlin J. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98: 27K–36K.
- 32 Nally JVJr. Acute renal failure in hospitalized patients. Cleve Clin J Med 2002; 69: 569–574.
- 33 Jones RH,Hannan EL,Hammermeister KE,Delong ER,O'Connor GT,Luepker RV,Parsonnet V,Pryor DB. Identification of preoperative variables needed for risk adjustment of short-term mortality after coronary artery bypass graft surgery. The Working Group Panel on the Cooperative CABG Database Project. J Am Coll Cardiol 1996; 28: 1478–1487.
- 34 O'Connor GT,Malenka DJ,Quinton H, et al. Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994-1996. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 1999; 34: 681–691.